CINCINNATI — Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2016 net revenues and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2016, management expects net revenue growth of 3% to 5% on a constant currency basis, a net revenue range of $195 to $200 million, and per share diluted earnings to be between $0.86 and $0.90. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.1 million at fiscal 2015 year end to 42.2 million at fiscal 2016 year end. The net revenues and earnings guidance provided in this press release is from expected internal growth and does not include net revenue from new products expected to be launched in 2016, or the impact of any acquisitions the Company might complete during fiscal 2016.

Management expects net revenue and earnings for fiscal year 2015 to be near the low end of the guidance range which is $193 million for net revenues, and $0.85 per share diluted earnings. The impact of foreign currency exchange rates assumed in our guidance versus those actually experienced, is estimated to have had a negative impact of over $3 million on net revenues.

John A. Kraeutler, Chairman and Chief Executive Officer, stated “In recent years our business has grown modestly, primarily by driving menu and market share for our illumigene® molecular platform and by expanding our Life Science unit via new product offerings and broadened global reach, offset by slower growth in our traditional immunoassay revenues. The recent FDA clearance to market for illumigene HSV I and II, plus the anticipated launch of illumigene Malaria in the first half of 2016, further strengthen the appeal of illumigene as a valuable multiple assay molecular platform for our expanding customer base.

Further, Meridian’s overall performance has been impacted by negative currency rates and continued strategic investments to maintain our scientific leadership. We continue to produce industry-leading return on investment and strong free cash flow. We are comfortable with our annual dividend rate. In fiscal 2016, we anticipate continued organic growth rates in the low to middle single-digit range. Clearly, as we have stated recently, we are committed to using our unleveraged financial condition to effect transactions that will add strategic growth to our business.”